Genflow Biosciences PLC Announces Mid-Year Operational and Corporate Summary

Mon, 13 Jul 2026 02:00:00 -0400

LONDON, UK / ACCESS Newswire / July 13, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or the "Company"), an emerging leader in the field of longevity research, provides a mid-year operational and corporate summary covering the six-month period to 30 June 2026.

No delays in the dog clinical trial: Positive preliminary interim results from the SLAB trial, followed by confirmation of sustained safety and efficacy at the three-month follow-up
Expansion of confidentiality agreements with additional Tier-1 animal health companies
Strategic technology collaboration with Acuitas Therapeutics ("Acuitas ") for fully funded, non-dilutive LNP delivery development
International patent

Genflow Biosciences PLC Announces Mid-Year Operational and Corporate Summary

Mon, 13 Jul 2026 02:00:00 -0400

No delays in the dog clinical trial: Positive preliminary interim results from the SLAB trial, followed by confirmation of sustained safety and efficacy at the three-month follow-up
Expansion of confidentiality agreements with additional Tier-1 animal health companies
Strategic technology collaboration with Acuitas Therapeutics ("Acuitas ") for fully funded, non-dilutive LNP delivery development
International patent

Genflow Biosciences PLC Announces Result of AGM

Mon, 29 Jun 2026 07:35:00 -0400

LONDON, UK / ACCESS Newswire / June 29, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") an emerging leader in the field of longevity research, is pleased to announce that all resolutions proposed at the Annual General Meeting held earlier today were duly passed by shareholders. The number of proxy votes for each resolution submitted prior to the meeting are presented below.

Proxy Voting Results

Ordinary Resolutions

Votes for

LONDON, UK / ACCESS Newswire / June 29, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") an emerging leader in the field of longevity research, is pleased to announce that all resolutions proposed at the Annual General Meeting held earlier today were duly passed by shareholders. The number of proxy votes for each resolution submitted prior to the meeting are presented below.

Proxy Voting Results

Ordinary Resolutions

Votes for

LONDON, UK / ACCESS Newswire / June 22, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") an emerging leader in the field of longevity research, today announces Gad Berdugo, Independent Non-Executive Chairman will attend the BIO International Convention June 22-25 in San Diego, California.

Mr. Berdugo will participate in the panel discussion titled: "RNA Therapeutics: Where Will We See the Greatest Technical Advances and Continued Clinical Validation in the Next 3-5 Years?"

The BIO International Convention is one of the world's largest biotechnology industry events, bringing together biotechnology companies, academic and research

Genflow Biosciences PLC Announces Participation at BIO International Convention 2026

Mon, 22 Jun 2026 02:00:00 -0400

LONDON, UK / ACCESS Newswire / June 22, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") an emerging leader in the field of longevity research, today announces Gad Berdugo, Independent Non-Executive Chairman will attend the BIO International Convention June 22-25 in San Diego, California.

Mr. Berdugo will participate in the panel discussion titled: "RNA Therapeutics: Where Will We See the Greatest Technical Advances and Continued Clinical Validation in the Next 3-5 Years?"

The BIO International Convention is one of the world's largest biotechnology industry events, bringing together biotechnology companies, academic and research

Genflow Biosciences PLC - Company to present at Animal Longevity Summit 2026

Wed, 17 Jun 2026 02:00:00 -0400

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

LONDON, UK / ACCESS Newswire / June 17, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") an emerging leader in the field of longevity research, today

Genflow Biosciences PLC - Company to present at Animal Longevity Summit 2026

Wed, 17 Jun 2026 02:00:00 -0400

LONDON, UK / ACCESS Newswire / June 17, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") an emerging leader in the field of longevity research, today

Genflow Biosciences PLC Announces Notice of AGM

Thu, 04 Jun 2026 02:00:00 -0400

Notice of Annual General Meeting and Board Changes

LONDON, UK / ACCESS Newswire / June 4, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases is pleased to announce that it will hold its Annual General Meeting ("AGM") at 11am on Monday 29 June 2026 at One Heddon Street, London, W1B 4BD.

The Notice of the AGM ("Notice") and Form of Proxy will shortly be available on the Company's website,

Genflow Biosciences PLC Announces Notice of AGM

Thu, 04 Jun 2026 02:00:00 -0400

Notice of Annual General Meeting and Board Changes

LONDON, UK / ACCESS Newswire / June 4, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases is pleased to announce that it will hold its Annual General Meeting ("AGM") at 11am on Monday 29 June 2026 at One Heddon Street, London, W1B 4BD.

The Notice of the AGM ("Notice") and Form of Proxy will shortly be available on the Company's website,

Genflow Biosciences PLC Announces Exercise of Warrants and Issue of Equity

Fri, 08 May 2026 05:50:00 -0400

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

Exercise of Warrants and Issue of Equity

LONDON, UK / ACCESS Newswire / May 8, 2026 / Genflow (LSE:GENF)(OTCQB:GENFF) ("Genflow" or the "Company"), a biotechnology company focused on the development of gene therapies for age-related diseases announces that it

Genflow Biosciences PLC Announces Exercise of Warrants and Issue of Equity

Fri, 08 May 2026 05:50:00 -0400

Exercise of Warrants and Issue of Equity

LONDON, UK / ACCESS Newswire / May 8, 2026 / Genflow (LSE:GENF)(OTCQB:GENFF) ("Genflow" or the "Company"), a biotechnology company focused on the development of gene therapies for age-related diseases announces that it

Genflow Biosciences PLC Announces Final Results

Thu, 30 Apr 2026 09:00:00 -0400

LONDON, UK / ACCESS Newswire / April 30, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), an emerging leader in the field of longevity research, focused

Genflow Biosciences PLC Announces Final Results

Thu, 30 Apr 2026 09:00:00 -0400

LONDON, UK / ACCESS Newswire / April 30, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), an emerging leader in the field of longevity research, focused

Genflow Biosciences PLC Announces Expansion of Confidentiality Agreements

Tue, 28 Apr 2026 02:00:00 -0400

Genflow Biosciences Plc

Expansion of Confidentiality Agreements with Tier-1 Animal Health Companies

LONDON, UK / ACCESS Newswire / April 28, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or the "Company"),

Genflow Biosciences PLC Announces Expansion of Confidentiality Agreements

Tue, 28 Apr 2026 02:00:00 -0400

Genflow Biosciences Plc

Expansion of Confidentiality Agreements with Tier-1 Animal Health Companies

LONDON, UK / ACCESS Newswire / April 28, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or the "Company"),

Genflow Biosciences PLC Announces Strategic Technology Collaboration

Mon, 20 Apr 2026 02:00:00 -0400

Genflow Biosciences Enters Strategic Technology Collaboration with Acuitas Therapeutics - Fully Funded, Non-Dilutive Access to World-Class LNP Delivery Platform

LONDON, UK / ACCESS Newswire / April 20, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or the "Company"), a European biotechnology company focused on the development of gene therapies for age-related diseases, today announces that it has entered into a strategic technology collaboration with Acuitas Therapeutics ("Acuitas"), a globally recognised leader in lipid nanoparticle ("LNP") delivery systems whose technology has underpinned some of the most commercially successful mRNA therapeutic programmes brought to market

Genflow Biosciences PLC Announces Strategic Technology Collaboration

Mon, 20 Apr 2026 02:00:00 -0400

Genflow Biosciences Enters Strategic Technology Collaboration with Acuitas Therapeutics - Fully Funded, Non-Dilutive Access to World-Class LNP Delivery Platform

Genflow Biosciences PLC Announces International Patent Publication

Mon, 13 Apr 2026 02:10:00 -0400

International Patent Publication Expands Protection for SIRT6-Based Muscular Disease Program

LONDON, UK / ACCESS Newswire / April 13, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or the "Company"), a European-based

Genflow Biosciences PLC Announces International Patent Publication

Mon, 13 Apr 2026 02:10:00 -0400

International Patent Publication Expands Protection for SIRT6-Based Muscular Disease Program

LONDON, UK / ACCESS Newswire / April 13, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or the "Company"), a European-based

Genflow Biosciences PLC Announces Total Voting Rights

Tue, 31 Mar 2026 02:45:00 -0400

LONDON, UK / ACCESS Newswire / March 31, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") announces that the total issued share capital of the Company as at 31 March 2026 consists of 535,653,205 ordinary shares of £0.0003 each, none of which are held in treasury. Therefore, the total number of voting rights in the Company is 535,653,205.

The figure of 535,653,205 ordinary shares may be used by shareholders of the Company as the denominator for the calculations by which they will determine if they are required to notify their investment

Genflow Biosciences PLC Announces Total Voting Rights

Tue, 31 Mar 2026 02:45:00 -0400

Genflow Biosciences PLC Announces Issue of Equity & PDMR Notifications

Thu, 05 Mar 2026 07:00:00 -0400

Successful Subscription to Raise £800,000 and PDMR Notifications

LONDON, UK / ACCESS Newswire / March 5, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or the "Company"), a European-based biotechnology company

Genflow Biosciences PLC Announces Issue of Equity & PDMR Notifications

Thu, 05 Mar 2026 07:00:00 -0400

Successful Subscription to Raise £800,000 and PDMR Notifications

LONDON, UK / ACCESS Newswire / March 5, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or the "Company"), a European-based biotechnology company

Genflow Biosciences PLC Announces Result of GM

Mon, 02 Mar 2026 07:55:00 -0400

Results of General Meeting

LONDON, UK / ACCESS Newswire / March 2, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") a leading European-based biotechnology company focusing on longevity, is pleased to announce that all resolutions proposed at the General Meeting held earlier today were duly passed by shareholders. The number of proxy votes for each resolution submitted prior to the meeting are presented below.

Proxy Voting Results

Ordinary Resolutions

Votes for

% of votes cast for

Votes Against

% of votes cast against

StreetInsider.com News Articles

Genflow Biosciences PLC Announces Mid-Year Operational and Corporate Summary

Genflow Biosciences PLC Announces Mid-Year Operational and Corporate Summary

Genflow Biosciences PLC Announces Result of AGM

Genflow Biosciences PLC Announces Participation at BIO International Convention 2026

Genflow Biosciences PLC - Company to present at Animal Longevity Summit 2026

Genflow Biosciences PLC - Company to present at Animal Longevity Summit 2026

Genflow Biosciences PLC Announces Notice of AGM

Genflow Biosciences PLC Announces Notice of AGM

Genflow Biosciences PLC Announces Exercise of Warrants and Issue of Equity

Genflow Biosciences PLC Announces Exercise of Warrants and Issue of Equity

Genflow Biosciences PLC Announces Final Results

Genflow Biosciences PLC Announces Final Results

Genflow Biosciences PLC Announces Expansion of Confidentiality Agreements

Genflow Biosciences PLC Announces Expansion of Confidentiality Agreements

Genflow Biosciences PLC Announces Strategic Technology Collaboration

Genflow Biosciences PLC Announces Strategic Technology Collaboration

Genflow Biosciences PLC Announces International Patent Publication

Genflow Biosciences PLC Announces International Patent Publication

Genflow Biosciences PLC Announces Total Voting Rights

Genflow Biosciences PLC Announces Total Voting Rights

Genflow Biosciences PLC Announces Issue of Equity & PDMR Notifications

Genflow Biosciences PLC Announces Issue of Equity & PDMR Notifications

Genflow Biosciences PLC Announces Result of GM